WASHINGTON - Nearly three months later than originally anticipated, the FDA Modernization and Accountability Act of 1997 became law.
WASHINGTON - Nearly three months later than originally anticipated, the FDA Modernization and Accountability Act of 1997 became law.
President Clinton signed the final version of the bill, which the pharmaceutical industry, the Food and Drug Administration and legislators had wanted to pass by Sept. 1, on Nov. 21.
"The word that we're getting from key health care policy people is that the President's happy with it," said Jeff Trewhitt, assistant vice president of communications for the Pharmaceutical Research and Manufacturers of America.
Legislators, most notably Sen. Ted Kennedy (D-Mass.), debated the bill's finer points for months. Kennedy alone fought for 26 amendments to the bill.
The final legislation includes a five-year renewal of the Prescription Drug User Fee Act, which will allow the FDA to collect as much as $600 million in user fees from pharmaceutical companies. It also facilitates access to experimental drugs for seriously ill patients, establishes a faster track for medicines and provides pharmaceutical companies with greater incentives to develop and test medicines for children.
The new law will speed drug approval times by an additional 10 to 16 months, according to Trewhitt. When added to the 12- to 15-month improvement that the original Prescription Drug User Fee Act made possible, time spent on the average 15-year drug approval process drops significantly. "By the turn of the century, patients are going to be getting new medicines two to two-and-a-half years faster than they did at the beginning of the decade," Trewhitt said.
In addition to renewing user fee collection, the new law allows companies more leeway to disseminate scientifically valid (but not FDA-approved) information about new uses for approved drugs. It also gives the FDA more flexibility as to how it may determine the effectiveness of a drug without weakening safety standards. PR
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.